Mitochondria-targeted phosphorescent cyclometalated iridium(III) complexes: synthesis, characterization, and anticancer properties

Cyclometalated iridium(III) complexes represent a promising approach to developing new anticancer metallodrugs. In this work, three phosphorescent cyclometalated iridium(III) complexes Ir1–Ir3 have been explored as mitochondria-targeted anticancer agents. All three complexes display higher antiproli...

Full description

Saved in:
Bibliographic Details
Published inJournal of biological inorganic chemistry Vol. 25; no. 4; pp. 597 - 607
Main Authors Li, Yi, Liu, Ben, Xu, Cui-Xia, He, Liang, Wan, Yi-Chao, Ji, Liang-Nian, Mao, Zong-Wan
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2020
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cyclometalated iridium(III) complexes represent a promising approach to developing new anticancer metallodrugs. In this work, three phosphorescent cyclometalated iridium(III) complexes Ir1–Ir3 have been explored as mitochondria-targeted anticancer agents. All three complexes display higher antiproliferative activity than cisplatin against the cancer cells screened, and with the IC 50 values ranging from 0.23 to 5.6 μM. Colocalization studies showed that these complexes are mainly localized in the mitochondria. Mechanism studies show that these complexes exert their anticancer efficacy through initiating a series of events related to mitochondrial dysfunction, including depolarization of mitochondrial membrane potential (MMP), elevation of intracellular reactive oxygen species (ROS) levels, and induction of apoptosis. Graphic abstract Mitochondria-targted cyclometalated iridium complexes induce apoptosis through depolarized mitochondria, elevation of intracellular ROS and activated caspase.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0949-8257
1432-1327
DOI:10.1007/s00775-020-01783-2